Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standardized FMT for Severe IBD
NCT02335281Phase 2Unknown
- Sponsor
- Yanling Wei
- Start
- Jan 2015
- Primary completion
- Oct 2017
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Fecal Microbiota Transplantation Capsule in inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's disease (2 arms), sponsored by Yanling Wei. Primary endpoint: Clinical remission at 1 year. Status: unknown.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
inflammatory bowel disease (IBD)ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT02335281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02335281.